Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Pancreatic cancer is a complex disease with diverse molecular characteristics.
• Identifying distinct molecular subgroups is crucial for targeted therapies and improved patient outcomes.

Purpose of the Study:

• To integrate multi-omics data (genomics, epigenomics, transcriptomics, clinical information) for pancreatic cancer.
• To identify novel molecular subgroups and prognostic biomarkers for pancreatic cancer.

Main Methods:

• Utilized The Cancer Genome Atlas (TCGA) data including DNA copy number variation, simple nucleotide variation, methylation, and mRNA expression.
• Performed integrated analysis to classify pancreatic cancer into four molecular subgroups (iC1, iC2, iC3, iC4).

Main Results:

• Identified four distinct molecular subgroups of pancreatic cancer.
• The iC1 subgroup demonstrated a better prognosis, higher immune score, fewer DNA copy number variations, and enhanced genomic stability.
• Discovered three novel genes (GRAP2, ICAM3, A2ML1) significantly correlated with patient prognosis.

Conclusions:

• Integrated multi-omics analysis offers novel insights into pancreatic cancer molecular classification.
• The identified subgroups and biomarkers may aid in developing new prognostic tools and understanding pancreatic cancer mechanisms.